Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter

Molecular and Cellular Biology

Volumn 17, Issue 11, 1997, Pages 6330-6338

  Bian, Junhui ^a   Sun, Yi ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ETOPOSIDE; GELATINASE A; LUCIFERASE; PROTEIN P53; RNA;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030826510     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.11.6330     Document Type: Article

References (62)

1. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. Mdm2 expression is induced by wildtype p53 activity. EMBO J. 12:461-468.
2. Bian, J., C. Jacobs, Y. Wang, and Y. Sun. 1996. Characterization of a putative p53 binding site in the promoter of the mouse tissue inhibitor of metalloproteinases-3 (TIMP-3) gene: TIMP-3 is not a p53 target gene. Carcinogenesis 17:2559-2562.
3. Birkedal-Hansen, H. 1995. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7:728-735.
4. Birkedal-Hansen, H., W. G. I. Moore, M. K. Bodden, L. J. Windsor, B. Birkedal-Hansen. 1992. Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 4:197-250.
5. Bouck, N. 1996. P53 and angiogenesis. Biochim. Biophys. Acta 1287:63-66.
6. Brown, P. D., A. T. Levy, I. M. K. Margulies, L. A. Liotta, and W. G. Stetler-Stevenson. 1990. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 50:6184-6191.
7. Chumakov, A. M., C. W. Miller, D. L. Chen, and H. P. Koeffler. 1993. Analysis of p53 transactivation through high-affinity binding sites. Oncogene 8:3005-3011.
8. Dameron, K. M., O. V. Volpert, M. A. Tainsky, and N. Bouck. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584.
9. Docherty, A. J., J. O'Connell, T. Crabbe, S. Angal and G. Murphy. 1992. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol. 10:200-207.
10. Donehower, L. A., and A. Bradley. 1993. The tumor suppressor p53. Biochim. Biophys. Acta 1155:181-205.
11. El-Deiry, W. S., S. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
12. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993 WAF-1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
13. Frisch, S. M., and J. H. Morisaki. 1990. Positive and negative transcriptional elements of the human type IV collagenase gene. Mol. Cell. Biol. 10:6524-6532.
14. Frisch, S. M., R. Reich, I. E. Collier, L. T. Genrich, G. Martin, and G. I. Goldberg. 1990. Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells. Oncogene 5:75-83.
15. Garbisa, S., R. Pozzatti, R. J. Muschel, U. Saffiotti, M. Ballin, R. H. Goldfarb, G. Khoury, and L. A. Liotta. 1987. Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res. 47:1523-1528.
16. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
17. Haffner, R., and M. Oren. 1995. Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev. 5:84-90.
18. Harendza, S., A. S. Pollock, P. R. Mertens, and D. H. Lovett. 1995. Tissue-specific enhancer-promoter interactions regulate high level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells. J. Biol. Chem. 270:18786-18796.
19. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. P53 mutations in human cancers. Science 253:49-53.
20. Huhtala, P. L. T. Chow, and K. Tryggvason. 1990. Structure of the human type IV collagenase gene. J. Biol. Chem. 265:11077-11082.
21. Hujanen, E. S., A. Vaisanen, A. Zheng, K. Tryggvason, and T. Turpeenniemi-Hujanen. 1994. Modulation of Mr 72,000 and Mr 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int. J. Cancer 58:582-586.
22. Kastan, M. B., C. E. Canman, and C. J. Leonard. 1995. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metast. Rev. 14:3-15.
23. Kastan, M. B., O. Zhan, W. S. El-Diery, F. Carrier, T. Jacks, W. F. Walsh, B. S. Pluckett, B. Vogelstein, and A. J. Forance, Jr. 1992. Participation of p53 protein in the cellular response to DNA damage. Cell 71:587-597.
24. Kinoshita, T., H. Sato, T. Takino, M. Itoh, T. Akizawa, and M. Seiki. 1996. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res. 56:2535-2538.
25. Ko, L. J., and C. Prives. 1996. P53: puzzle and paradigm. Genes Dev. 10:1054-1072.
26. Kohn, E. C., W. Jacob, Y. S. Kim, R. Alessandro, W. G. Stetler-Stevenson, and L. A. Liotta. 1994. Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J. Biol. Chem. 269:21505-21511.
27. Labrecque, S., and G. J. Matlashewski. 1995. Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: the use of human papillomavirus E6 to target p53. Oncogene 11:387-392.
28. Lane, D. P. 1994. p53 and human cancers. Br. Med. Bull. 50:582-599.
29. Levy, A. T., V. Cioce, M. E. Sobel, S. Garbisa, W. F. Grigioni, L. A. Liotta, and W. G. Stetler-Stevenson. 1991. Increased expression of the Mr 72,000 type IV collagenase in human colonie adenocarcinoma. Cancer Res. 51:439-444.
30. Liotta, L. A., P. S. Steeg, and W. G. Stetler-Stevenson. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336.
31. Ludes-Meyers, J. H., M. A. Subler, C. V. Shivakumar, R. M. Munoz, P. Jiang, J. E. Bigger, D. R. Brown, S. P. Deb, and S. Deb. 1996. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol. 16:6009-6019.
32. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
33. Montgomery, A. M. P., Y. A. De Clerk, K. E. Langley, R. A. Reisfeld, B. M. Mueller. 1993. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res. 53:693-700.
34. Morris, G. F., J. R. Bischoff, and M. B. Mathews. 1996. Transcriptional activation of the human proliferating cell nuclear antigen promoter by p53. Proc. Natl. Acad. Sci. USA 93:895-899.
35. Mummenbrauer, T., F. Janus, B. Muller, L. Wiesmuller, W. Deppert, and F. Grosse. 1996. P53 protein exhibits 3′-to-5′ exonuclease activity. Cell 85: 1089-1099.
36. Murphy, M., A. Hinman, and A. J. Levine. 1996. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 10:2971-2980.
37. Nakajima, M., D. Lotan, M. M. Baig, R. M. Carralero, W. R. Wood, M. J. C. Hendrix, and R. Lotan. 1989. Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res. 49:1698-1706.
38. Okamoto, K., and D. Beach. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13:4816-4822.
39. Ory, K., Y. Legros, C. Auguin, and T. Soussi. 1994. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13:3496-3504.
40. Pepper, M. S., J.-D. Vassalli, J. W. Wilks, L. Schweigerer, L. One, and R. Montesano. 1994. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J. Cell. Biochem. 55:419-434.
41. Selivanova, G., and K. G. Wiman. 1995. p53: a cell cycle regulator activated by DNA damage. Adv. Cancer Res. 66:143-180.
42. Shivakumar, C. V., D. R. Brown, S. Deb, and S. P. Deb. 1995. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol. Cell. Biol. 15:6785-6793.
43. Singh, R. K., M. Gutman, R. Reich, and M. Bar-Eli. 1995. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res. 55:3669-3674.
44. Somasundaram, K., G. Jayaraman, T. Williams, E. Moran, S. Frisch, and B. Thimmapaya. 1996. Repression of a matrix metalloproteinase gene by E1A correlates with its ability to bind to cell type-specific transcription factor AP-2. Proc. Natl. Acad. Sci. USA 93:3088-3093.
45. Stetler-Stevenson, W. G., S. Aznavoorian, and L. A. Liotta. 1993. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9:541-573.
46. Strongin, A. Y., I. Collier, G. Bannikov, B. L. Marmer, G. A. Grant, and G. I. Goldberg. 1995. Mechanism of cell surface activation of 72-kDa type IV collagenase. J. Biol. Chem. 270:5331-5338.
47. Sun, Y., J. Bian, Y. Wang, and C. Jacobs. 1997. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. Oncogene 14:385-393.
48. Sun, Y., Z. Dong, K. Nakamura, and N. H. Colburn. 1993. Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. FASEB J. 7:944-950.
49. Sun, Y., G. Hegamyer, and N. H. Colburn. 1994. Molecular cloning of five mRNAs differentially expressed in preneoplastic or neoplastic mouse JB6 epidermal cells: one is homologous to human tissue inhibitor of metalloproteinases-3. Cancer Res. 54:1139-1144.
50. Sun, Y., G. Hegamyer, H. Kim, K. Sithanandam, H. Li, R. Watts, and N. H. Colburn. 1995. Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter. J. Biol. Chem. 270:19312-19319.
51. Sun, Y., Y. Pommier, and N. H. Colburn. 1992. Acquisition of a growth-inhibitory response to phorbol ester involves DNA damage. Cancer Res. 52:1907-1915.
52. Tishler, R. B., S. K. Calderwood, C. N. Coleman, and B. D. Price. 1993. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res. 53:2212-2216.
53. Vojta, P. J., and J. C. Barrett. 1995. Genetic analysis of cellular senescence. Biochim. Biophys. Acta 1242:29-41.
54. Wang, Q., G. P. Zambetti, and D. P. Suttle. 1997. Inhibition of DNA topoisomerasc IIα gene expression by the p53 tumor suppressor. Mol. Cell. Biol. 17:389-397.
55. Whitacre, C. M., H. Hashimoto, M.-L. Tsai, S. Chatterjee, S. J. Berger, and N. A. Berger. 1995. Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res. 55:3697-3701.
56. Williams, T., and R. Tjian. 1991. Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. Genes Dev. 5:670-682.
57. Woessner, J. F., Jr. 1991. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:2145-2154.
58. Young, T. N., S. V. Pizzo, and M. S. Stack. 1995. A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinases-2. J. Biol. Chem. 270:999-1002.
59. Yu, M., H. Sato, M. Seiki, and E. W. Thompson. 1995. Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res. 55:3272-3277.
60. WAF1/CIP1 expression. Nat. Genet. 15: 78-82.
61. Zhang, W., J. W. Shay, and A. Deisseroth. 1993. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53. Cancer Res. 53:4772-4775.
62. Zhang, W., X.-Y. Guo, G.-Y. Hu, W.-B. Liu, J. W. Shay, and A. B. Deisseroth. 1994. A temperature-sensitive mutant of human p53. EMBO J. 13:2535-2544.